Aspire Biopharma closes SPAC merger, lists on Nasdaq; enters $100M equity line

Aspire Biopharma Holdings, Inc.

Completed business combination with PowerUp Acquisition Corp.; began trading on Nasdaq Feb 20 under ASBP/ASBPW.
Proceeds from transaction total approx $3.8M including trust account and PIPE financing.
Entered $100M ELOC agreement with Arena; 96% of VWAP with $4.00 floor; 1,893,473 commitment shares issued.
Lead product is fast-absorbing aspirin for cardiology emergencies; plans FDA fast track 505(b)(2) NDA.
Management led by CEO Kraig Higginson; board of seven directors including Michael Howe, Gary E. Stein.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.